Jason C. Rech, Ph.D. - Publications

University of Pittsburgh, Pittsburgh, PA, United States 
Reaction Design, Total Synthesis, Mechanistic Analysis, Diversity Oriented Synthesis

21/26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Rech JC, Bhattacharya A, Branstetter BJ, Love CJ, Leenaerts JE, Cooymans LP, Eckert WA, Ao H, Wang Q, Chaplan SR, Wickenden AD, Lebsack AD, Breitenbucher JG. The discovery and preclinical characterization of 6-chloro-N-(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonists. Bioorganic & Medicinal Chemistry Letters. PMID 27595421 DOI: 10.1016/j.bmcl.2016.08.029  1
2016 Swanson DM, Savall BM, Coe KJ, Schoetens F, Koudriakova T, Skaptason J, Wall J, Rech JC, Deng X, De Angelis M, Everson A, Lord B, Wang Q, Ao H, Scott B, et al. The Identification of (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a small molecule antagonist of the P2X7 receptor. Journal of Medicinal Chemistry. PMID 27548392 DOI: 10.1021/acs.jmedchem.6b00989  1
2016 Rech JC, Bhattacharya A, Letavic MA, Savall BM. The evolution of P2X7 antagonists with a focus on CNS indications. Bioorganic & Medicinal Chemistry Letters. PMID 27426304 DOI: 10.1016/j.bmcl.2016.06.048  1
2016 Amhaoul H, Ali I, Mola M, Van Eetveldt A, Szewczyk K, Missault S, Bielen K, Kumar-Singh S, Rech J, Lord B, Ceusters M, Bhattacharya A, Dedeurwaerdere S. P2X7 receptor antagonism reduces severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. Neuropharmacology. PMID 26775823 DOI: 10.1016/j.neuropharm.2016.01.018  1
2016 Chrovian CC, Soyode-Johnson A, Ao H, Bacani GM, Carruthers NI, Lord B, Nguyen L, Rech JC, Wang Q, Bhattacharya A, Letavic MA. Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. Acs Chemical Neuroscience. PMID 26752113 DOI: 10.1021/acschemneuro.5b00303  1
2015 Ameriks MK, Ao H, Carruthers NI, Lord B, Ravula S, Rech JC, Savall BM, Wall JL, Wang Q, Bhattacharya A, Letavic MA. Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. PMID 26707399 DOI: 10.1016/j.bmcl.2015.12.052  1
2015 Rudolph DA, Alcazar J, Ameriks MK, Anton AB, Ao H, Bonaventure P, Carruthers NI, Chrovian CC, De Angelis M, Lord B, Rech JC, Wang Q, Bhattacharya A, Andres JI, Letavic MA. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorganic & Medicinal Chemistry Letters. PMID 26099534 DOI: 10.1016/j.bmcl.2015.06.004  1
2014 Chrovian CC, Rech JC, Bhattacharya A, Letavic MA. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. Progress in Medicinal Chemistry. 53: 65-100. PMID 24418608 DOI: 10.1016/B978-0-444-63380-4.00002-0  1
2013 Letavic MA, Lord B, Bischoff F, Hawryluk NA, Pieters S, Rech JC, Sales Z, Velter AI, Ao H, Bonaventure P, Contreras V, Jiang X, Morton KL, Scott B, Wang Q, et al. Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists. Acs Medicinal Chemistry Letters. 4: 419-22. PMID 24900687 DOI: 10.1021/ml400040v  1
2011 Wan S, Wu F, Rech JC, Green ME, Balachandran R, Horne WS, Day BW, Floreancig PE. Total synthesis and biological evaluation of pederin, psymberin, and highly potent analogs. Journal of the American Chemical Society. 133: 16668-79. PMID 21902245 DOI: 10.1021/Ja207331M  1
2011 Maher MP, Bhattacharya A, Ao H, Swanson N, Wu NT, Freedman J, Kansagara M, Scott B, Li DH, Eckert WA, Liu Y, Sepassi K, Rizzolio M, Fitzgerald A, Liu J, ... ... Rech JC, et al. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist. European Journal of Pharmacology. 663: 40-50. PMID 21575625 DOI: 10.1016/J.Ejphar.2011.05.001  1
2010 Rech JC, Eckert WA, Maher MP, Banke T, Bhattacharya A, Wickenden AD. Recent advances in the biology and medicinal chemistry of TRPA1. Future Medicinal Chemistry. 2: 843-58. PMID 21426205 DOI: 10.4155/fmc.10.29  1
2010 Lebsack AD, Rech JC, Branstetter BJ, Hawryluk NA, Merit JE, Allison B, Rynberg R, Buma J, Rizzolio M, Swanson N, Ao H, Maher MP, Herrmann M, Freedman J, Scott BP, et al. 1,2-diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties. Bioorganic & Medicinal Chemistry Letters. 20: 7142-6. PMID 20932750 DOI: 10.1016/j.bmcl.2010.09.006  1
2008 Green ME, Rech JC, Floreancig PE. Total synthesis of theopederin D Angewandte Chemie - International Edition. 47: 7317-7320. PMID 18683833 DOI: 10.1002/Anie.200802548  1
2007 Nakagawa H, Rech JC, Sindelar RW, Ellman JA. Catalytic enantioselective addition of arylboronic acids to N-boc imines generated in situ. Organic Letters. 9: 5155-7. PMID 17988138 DOI: 10.1021/Ol702045W  1
2007 Rech JC, Yato M, Duckett D, Ember B, LoGrasso PV, Bergman RG, Ellman JA. Synthesis of potent bicyclic bisarylimidazole c-Jun N-terminal kinase inhibitors by catalytic C-H bond activation. Journal of the American Chemical Society. 129: 490-1. PMID 17227002 DOI: 10.1021/Ja0676004  1
2005 Rech JC, Floreancig PE. Concise and stereoselective synthesis of the N7-C25 fragment of psymberin Organic Letters. 7: 5175-5178. PMID 16268531 DOI: 10.1021/Ol0520267  1
2005 Green ME, Rech JC, Floreancig PE. Stereochemical assignment of the C1-C6 fragment of psymberin by synthesis and natural product degradation Organic Letters. 7: 4117-4120. PMID 16146366 DOI: 10.1021/Ol051396S  1
2004 Aubele DL, Rech JC, Floreancig PE. Catalytic Aerobic Generation of Acyliminium Ions through Electron‐Transfer‐Mediated Carbon‐Carbon Bond Activation Advanced Synthesis & Catalysis. 346: 359-366. DOI: 10.1002/Adsc.200303173  1
2004 Aubele DL, Rech JC, Floreancig PE. Catalytic aerobic generation of acyliminium ions through electron-transfer-mediated carbon-carbon bond activation Advanced Synthesis and Catalysis. 346: 359-366.  1
2003 Rech JC, Floreancig PE. An oxidative entry into the amido trioxadecalin ring system Organic Letters. 5: 1495-1498. PMID 12713307 DOI: 10.1021/Ol034273L  1
Low-probability matches
2020 Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Science Translational Medicine. 12. PMID 33268508 DOI: 10.1126/scitranslmed.aaz2841  0.12
2019 Chrovian CC, Soyode-Johnson A, Wall JL, Rech JC, Schoellerman J, Lord B, Coe KJ, Carruthers NI, Nguyen L, Jiang X, Koudriakova T, Balana B, Letavic MA. 1-Pyrrolo[3,2-]pyridine GluN2B-Selective Negative Allosteric Modulators. Acs Medicinal Chemistry Letters. 10: 261-266. PMID 30891123 DOI: 10.1021/acsmedchemlett.8b00542  0.08
2018 Ramadan AM, Daguindau E, Rech JC, Chinnaswamy K, Zhang J, Hura GL, Griesenauer B, Bolten Z, Robida A, Larsen M, Stuckey JA, Yang CY, Paczesny S. From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. Jci Insight. 3. PMID 30046004 DOI: 10.1172/jci.insight.99208  0.01
2009 Floreancig P, Green M, Rech J. Synthesis of Theopederin D Synfacts. 2009: 0234-0234. DOI: 10.1055/S-0028-1087699  0.01
2005 Atti-Santos AC, Rossato M, Pauletti GF, Rota LD, Rech JC, Pansera MR, Agostini F, Serafini LA, Moyna P. Physico-chemical evaluation of Rosmarinus officinalis L. Essential oils Brazilian Archives of Biology and Technology. 48: 1035-1039. DOI: 10.1590/S1516-89132005000800020  0.01
Hide low-probability matches.